جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

18 مُخرَج نتائج البحث عن «Diabetic nephropathy»

مقالوصول مفتوح20253استشهاد· Semantic Scholar

Khellin a promising natural compound for alleviation of diabetic nephropathy: Evidence from in-silico, in-vitro and in-vivo studies

Journal of Radiation Research and Applied Sciences · مجلد 18 (3) · 101590-101590

Objective This study aimed to evaluate the potential impacts of Khellin (Khe) therapeutic potential in streptozotocin (STZ)-induced diabetic nephropathy (DN) using integrated in silico, in vitro, and in vivo approaches. Methods In silico studies were conducted to assess whether Khe could target DN-associated proteins. In vitro, the MTT assay assessed Khe's impact on normal kidney HK-2 cells. In vivo, male Sprague Dawley rats (n = 30) were randomly divided into six groups: normal control (Cnt), low (Khe-L, 50 mg/kg), and high (Khe-H, 100 mg/kg) dose Khe, DN, DN + Khe-L, and DN + Khe-H. Renal function markers, oxidative stress parameters, inflammatory cytokines, and apoptotic genes were evaluated. Histopathological examination of kidney tissues was also performed. Results Khe showed variable binding affinities and interaction patterns in a molecular docking study against seven proteins (TNFα, TGFβ1, ETS1, TIMP2, MAPK14, PI3K, and KIM1) involved in DN pathogenesis. In vitro, Khe improved the survival of high glucose (HG) treated HK-2 cells and inhibited the activation of MAPK14, PI3K, caspase 3, and TNFα induced by HG. Khe-treated rats (DN + Khe-L, and DN + Khe-H) exhibited significantly 1) decreased serum levels of creatinine, urea, and retinol-binding protein (RBP), 2) declined urinary proteins levels, 3) reduced renal levels of MDA, 4) increased activities of the antioxidant enzymes (SOD, CAT, GPx), 5) downregulated renal expression of TNFα, TGFβ1, ETS1, TIMP2, KIM1, MAPK14, PI3K, and Bax , and 6) upregulated expression of Bcl2 compared to the DN group. These biochemical and molecular results were corroborated by histopathological examination, which showed that the groups treated with Khe had much better kidney tissue integrity. The effectiveness of the treatment depended on the dosage. Conclusion Khe exhibited therapeutic effects in DN, potentially mediated by its antioxidant, anti-apoptotic, and anti-inflammatory mechanisms. These findings underscore Khe's promise as an adjunctive therapy for DN.

khellindiabetic nephropathystreptozotocin-induced diabetesHK-2 cells
مقالوصول مفتوح20252استشهاد· Semantic Scholar

Epidemiology of Macrovascular and Microvascular Complications Among Patients With Diabetes Mellitus in Primary Care in Bahrain

Cureus · مجلد 17 (12) · e99184-e99184

Introduction Although diabetes mellitus (DM) is a leading cause of cardiovascular complications, few studies have evaluated the epidemiology of these complications in primary care in Bahrain. Since data from primary care settings are particularly important, as most patients with diabetes are managed in this setting, this study aimed to determine the prevalence and predictors of diabetic complications among patients attending primary healthcare centers in Bahrain. Methods A cross-sectional study was conducted among adult patients with DM attending diabetic clinics in primary care centers across Bahrain. Demographic, clinical, and laboratory data, and diabetes complications were collected. Microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (stroke, acute coronary syndrome, peripheral arterial disease) complications were assessed. Descriptive and inferential analyses were performed. Results A total of 585 patients were enrolled, with a median age of 61±14 years. Most patients were males (n=326, 55.7%), had type 2 DM (n=566, 96.8%), and had uncontrolled diabetes (n=349, 59.7%). Approximately half of the patients (51.6%) had at least one diabetes-related complication. Neuropathy (n=158, 27.0%) and retinopathy (n=89, 15.2%) were the most frequent microvascular complications, while peripheral vascular disease (n=64, 10.9%) and ischemic heart disease (n=61, 10.4%) were the leading macrovascular complications. Multivariable analysis revealed that higher total cholesterol (OR=1.326, p=0.031) and lower estimated glomerular filtration rate, eGFR (OR=1.009, p=0.025) predicted macrovascular complications. Diabetic foot ulcers increased macrovascular complications by 14-fold (p<0.001). Predictors of microvascular complications included type 2 DM (OR=16.277, p=0.011), longer DM duration (OR=1.156, p<0.001), higher triglycerides (OR=1.222, p=0.045), dyslipidemia (p=0.036), and foot ulcers (27-fold; p=0.002). Conclusion Diabetic complications were prevalent among diabetic patients in Bahrain, especially those with impaired renal function, dyslipidemia, anemia, and foot ulcers. Early identification and management of these comorbidities is crucial to prevent diabetes-related complications.

diabetes mellitusdiabetes complicationsmacrovascular complicationsmicrovascular complications
نسخة أوليةمفتوح (مستودع)2025

Therapeutic potential of mesenchymal stem cells-derived exosomes loaded with elemental or nano selenium on diabetic nephropathy

Research Square

Abstract Endocrinologists and nephrologists continually seek new therapeutic approaches for diabetic nephropathy (DN). Lately, mesenchymal stem cells (MSCs)-derived exosomes (MSCs-EXs) have been applied as natural carriers for targeted drug delivery. Thus, we aim to estimate the therapeutic potentialities of MSCs-EXs loaded with ordinary selenium (Se) or its nanoform (NSe) as a promising cell-free therapy in diabetic nephropathy (DN). Eighty rats were randomly split into 8 groups; control, EXs, EXs + Se, EXs + NSe, diabetic (D), D + EXs, D + EXs + Se, and D + EXs + NSe groups. After 4 weeks, our results indicated renal hypolipidemic and renal ameliorating effects of unloaded or loaded EXs with Se or NSe, evidenced by the declined serum levels of urea, uric acid, and creatinine, compared to diabetic-untreated rats. Such observations might be a reflection of the observed antioxidant activity of both EXs alone or in the combined form with either Se or NSe, evidenced by decreased renal MDA, NO, H2O2 levels coupled with increased GSH, SOD, CAT, and GPX, besides their anti-inflammatory and antiapoptotic effects, indicated by the decreased renal levels of IL-6, TGF-β, TNF-α, BAX, caspase-3, and P53, with Bcl-2 upregulation. Consequently, the kidney architecture in the three diabetic-treated groups was greatly improved. Likely, the EXs-loaded NSe treatment protocol highlighted the DN improvement superiority most significantly compared to the other protocols.

diabetic nephropathymesenchymal stem cell-derived exosomesselenium nanoparticlesselenium
مقالوصول مفتوح202310استشهاد· Semantic Scholar

DPP-4i versus SGLT2i as modulators of PHD3/HIF-2α pathway in the diabetic kidney

Biomedicine & Pharmacotherapy · مجلد 167 · 115629-115629

RATIONALE: Renal hypoxia is one of the currently highlighted pathophysiologic mechanisms of diabetic nephropathy (DN). Both hypoxia-inducible factor-1α (HIF-1α) and HIF-2α are major regulators of renal adaptive responses to hypoxia. OBJECTIVES: This study aims to compare the effects of vildagliptin (a dipeptidyl peptidase-IV inhibitor, DPP-4i) and empagliflozin (a sodium-glucose cotransporter 2 inhibitor, SGLT2i) on the differential expression of renal HIF-1α/2α. Tissue expression of prolylhydroxylase 3 (PHD3), a key regulator of HIF-2α stability, was also highlighted in a diabetic nephropathy rat model. Type 1 diabetes mellitus was induced and diabetic rats were treated with either Vildagliptin or Empagliflozin (10 mg/kg/d each) for 12 weeks. Improvements in the kidney functional and histopathological parameters were addressed and correlated to changes in the renal expression of HIF-1α/2α, and PHD3. Urinary KIM-1 concentration was tested as a correlate to HIF pathway changes. FINDINGS: Both vildagliptin- and empagliflozin-treated groups exhibited significant improvement in the functional, pathological, and ultra-structural renal changes induced by chronic diabetes. Compared to the untreated group, renal gene expression of HIF-1α was decreased while that of HIF-2α was increased in both treated groups, with significantly greater effects observed with SGLT2i. Renal PHD3 immune-reactivity was also decreased by both drugs, again with better efficacy for the SGLT2i. Importantly, improvements in the diabetic kidney biochemical and structural biomarkers were significantly correlated to PHD3 reductions and HIF-2α increments. CONCLUSIONS: Both DPP-4i and SGLT2i could delay the progression of DN through their differential modulating effects on the PHD3/ HIF-2α pathway with significantly better efficacy for SGLT2i.

diabetic nephropathyvildagliptinempagliflozinDPP-4 inhibitors
مقالمفتوح (مستودع)2023

In World Diabetes Day, assessment of the chronic diseases among general population in Riyadh, KSA

Medical Science · مجلد 27 (133)

Background: Every year World Diabetes Day (WDD) is celebrated on 14November all across the globe to raise awareness about the diabetes and its prevention, complications and treatment.Complications include macrovascular conditions, such as coronary heart disease, stroke and microvascular, including diabetic nephropathy, retinopathy and peripheral neuropathy.We aim to assess the relationship between random glucose blood glucose and chronic diseases.Methods: A cross-sectional study in Riyadh on November 2021 and January 2022 at a public shopping center.Data collection sheet was prepared for age, weight, gender, hypertension, diabetes mellitus, ischemic heart disease, random blood glucose and Glucometer devices were used to gather the data.One of the volunteers took a visitor's random blood glucose reading and weight in kilograms using a mechanical scale.Data analyzed using SPSS.Result: Majority of participants was male (54%) with age group from 30-39 years old (29.3%) with weight in kilo gram from 60-79 (43.4%).Prevalence of diabetes was (18%) and hypertension (17%) and ischemic heart disease (1.8%).Relation between age and RBG (p value= 0.000) and between weight and RBG (p value=0.243).Conclusion: According to this study, Saudi Arabia is one of the average countries in terms of the number of diabetic patients.High prevalence of diabetics, especially men in the 30-to 39year-old age group who weight between 60 and 79 kg.Almost majority of the patients had hypertension in addition to diabetes.The statistical relationship between age and random blood glucose was significant.

diabetes mellitusWorld Diabetes Dayrandom blood glucosehypertension
مقالوصول مفتوح202245استشهاد· Semantic Scholar

Calycosin modulates NLRP3 and TXNIP-mediated pyroptotic signaling and attenuates diabetic nephropathy progression in diabetic rats; An insight

Biomedicine & Pharmacotherapy · مجلد 155 · 113758-113758

Diabetic nephropathy [DN] is one of the most prevalent microvascular complications of diabetes mellitus [DM] and it is considered a leading cause of kidney failure. In this study calycosin, an isoflavone that constitutes the major constituent in Radix Astragali with numerous pharmacological merits was investigated as reno-protective agent against DN and also the potential underlying mechanisms were investigated. Streptozotocin (STZ) (40 mg/kg) was injected in the peritoneal cavity of male Sprague-Dawely rats to induce DM. For ten weeks, calycosin (5 and 10 mg/kg), and NAC (500 mg/kg) were orally administered and they significantly lowered blood glucose levels, but significantly increased insulin levels. Calycosin improved the deteriorated kidney functions as evidenced in retracted serum creatinine, albuminuria, blood urea nitrogen, and proteinuria levels. Meanwhile, urine creatinine clearance significantly escalated. Furthermore, biomarkers of cell injury; LDH activity, significantly declined and kidney content of NO markedly decreased as well. Inflammation, fibrosis and oxidative stress were manifested by increased serum levels of IL-1β, renal NF-κBp65, NLRP3, TXNIP and MDA contents with declined levels of IL-10 and TAC and decreased Nrf2 expression. The above-mentioned biomarkers were significantly improved with calycosin treatment which modulated NF-κB/p65/NLRP3/TXNIP signaling, oxidative stress, inflammatory cytokines and fibrotic processes; Thus, implying a reno-protective impact. This was associated with improvement in renal histopathological and immune-histopathological parameters; H&E, Masson Trichrome and Nrf-2. Based on these findings, calycosin can be presumed to be a promising drug for hindering the development of DN through modulation of NF-κB/p65/NLRP3/TXNIP inflammasome signaling pathway.

calycosindiabetic nephropathyNLRP3 inflammasomeTXNIP
مقالوصول مفتوح202236استشهاد· Semantic Scholar

Metformin suppresses LRG1 and TGFβ1/ALK1-induced angiogenesis and protects against ultrastructural changes in rat diabetic nephropathy

Biomedicine & Pharmacotherapy · مجلد 158 · 114128-114128

Diabetic nephropathy (DN) has high prevalence and poor prognosis which make it a research priority for scientists. Since metformin, a hypoglycaemic drug, has been found to prolong the survival of mice with DN. This study aims at investigating the molecular mechanisms leading to DN in rats and to explore the role of leucine-rich α-2-glycoprotein-1 (LRG1), activin-like kinase1 (ALK1), and transforming growth factor-β (TGFβ1) in the pathologic alterations seen in DN. The aim was also extended to explore the protective action of metformin against DN in rats and its influence on LRG1and ALK1/TGFβ1 induced renal angiogenesis. 24 male rats were used. Rats were assigned as, the vehicle group, the diabetic control group and diabetic + metformin (100 and 200 mg/kg) groups. Kidney samples were processed for histopathology, immunohistochemistry and biochemical analysis. Bioinformatic analysis of studied proteins was done to determine protein-protein interactions. Metformin reduced serum urea and creatinine significantly, decreased the inflammatory cytokine levels and reduced LRG1, TGFβ1, ALK1 and vascular endothelial growth factor (VEGF) proteins in rat kidneys. Bioinformatic analysis revealed interactions between the studied proteins. Metformin alleviated the histopathological changes observed in the diabetic rats such as the glomerular surface area and increased Bowman's space diameter. Metformin groups showed decreased VEGF immunostaining compared to diabetic group. Metformin shows promising renoprotective effects in diabetic model that was at least partly mediated by downregulation of LRG1 and TGFβ1/ALK1-induced renal angiogenesis. These results further explain the molecular mechanism of metformin in DN management.

metformindiabetic nephropathyLRG1TGF-β1
مراجعةوصول مفتوح202226استشهاد· Semantic Scholar

Insights into the Uses of Traditional Plants for Diabetes Nephropathy: A Review

Current Issues in Molecular Biology · مجلد 44 (7) · 2887-2902

Diabetic nephropathy (DN) is a serious kidney illness characterized by proteinuria, glomerular enlargement, reduced glomerular filtration, and renal fibrosis. DN is the most common cause of end-stage kidney disease, accounting for nearly one-third of all cases of diabetes worldwide. Hyperglycemia is a major factor in the onset and progression of diabetic nephropathy. Many contemporary medicines are derived from plants since they have therapeutic properties and are relatively free of adverse effects. Glycosides, alkaloids, terpenoids, and flavonoids are among the few chemical compounds found in plants that are utilized to treat diabetic nephropathy. The purpose of this review was to consolidate information on the clinical and pharmacological evidence supporting the use of a variety of medicinal plants to treat diabetic nephropathy.

diabetic nephropathymedicinal plantstraditional medicinephytochemicals
مقالوصول مفتوح202215استشهاد· Semantic Scholar

Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury—Insight into Oxidative Injury/Inflammation/Apoptosis Modulation

Life · مجلد 12 (5) · 764-764

In this study, we aim to explore the beneficial therapeutic impacts of dapagliflozin (Dapa), a highly potent, reversible, and selective sodium-glucose cotransporter-2 inhibitor, and liraglutide (Lira), a glucagon-like peptide-1 (GLP-1) receptor agonist, as hypoglycaemic agents for the management of diabetes mellitus (DM), as well as their combination against DM-induced complications, including hepato-renal injury. Indeed, the progression of DM was found to be associated with significant hepatic and renal injury, as confirmed by the elevated biochemical indices of hepatic and renal functions, as well as histopathological examination. Dapa, Lira, and their combination effectively attenuated DM-induced hepatic and renal injury, as confirmed by the recovery of hepatic and renal functional biomarkers. The administration of both drugs significantly reduced the tissue contents of MDA and restored the contents of GSH and catalase activity. Moreover, NF-κB and TNF-α expression at the protein and gene levels was significantly reduced in the liver and the kidney. This was in parallel with the significant reduction in the caspase-3 content in the liver and the kidney, as well as suppressed cleaved caspase-3 expression in the hepatic and renal specimens, as confirmed by immune-histochemical analysis. Notably, the combined Dapa/Lira treatment demonstrated an additive superior hepato-renal protective impact compared with the use of either drug alone. Thus, it appears that Dapa and Lira, through the coordinated modulation of oxidative, inflammatory, and apoptotic signalling, confer a significant hepato-renal protective impact against DM-induced complications and tissue injury.

dapagliflozinliraglutidecombination therapydiabetes complications
مراجعةوصول مفتوح202137استشهاد· Semantic Scholar

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Journal of Infection and Public Health · مجلد 14 (8) · 1075-1086

The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries, including Saudi Arabia, since 2020. The generic structure of remdesivir was first disclosed in 2009. This patent review summarizes the remdesivir based inventions to treat/prevent COVID-19 and other disorders from 2009 to May 16, 2021, emphasizing the patents related to medical and pharmaceutical sciences. The primary patents/patent applications of remdesivir are related to its compositions, new combinations with other therapeutic agents, delivery systems, and new indications. The inventive combinations have displayed synergistic effects against COVID-19, whereas the delivery systems/compositions have improved patient compliance. The inventions related to new indications of remdesivir to treat Ebola, hepatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and cardiovascular complications enhance its therapeutic area. Many new innovative combinations and delivery systems of remdesivir are anticipated to provide better treatment for COVID-19.

remdesivirCOVID-19 pandemicpatentscombination therapy
مقالوصول مفتوح202129استشهاد· Semantic Scholar

RETRACTED: Phenethyl isothiocyanate attenuates diabetic nephropathy via modulation of glycative/oxidative/inflammatory signaling in diabetic rats

Biomedicine & Pharmacotherapy · مجلد 142 · 111666-111666

Diabetic nephropathy (DN) is a diabetic complication characterized by disruption of renal microvasculature, reactive oxygen species accumulation and increased inflammation, all of which contribute to renal injury. Phenethyl isothiocyanate (PEITC) is a naturally occurring isothiocyanate well known for its antioxidant and anti-inflammatory effects, yet its reno-preventive effects against DN has not been investigated. The current study looked into the in vivo reno-protective effects of PEITC in STZ-induced DN in rats. PEITC (3, 10 and 30 mg/kg) was administered orally for 8 weeks post DM establishment. PEITC treatment significantly improved kidney and liver functions, renal histopathological features, tissue fibrosis, macrophage infiltration and blood glucose levels compared to DN control. Mechanistically, PEITC treatment alleviated DN-induced renal damage via modulating glycation and oxidative stresses and inflammatory response. As such, PEITC activated glyoxalase 1 (GLO1) that induced a retraction in renal tissue expression of advanced glycation end products (AGEs) and its receptor (RAGE). PEITC activated nuclear erythroid 2-related factor 2 (Nrf2) and increased expression of its downstream targets, hemeoxygenase-1 (HO-1) and gamma glutamate-cysteine (γ-GCS). Additionally, PEITC treatment decreased the expression of Nrf2 repressor protein, keap1. The anti-inflammatory effect of PEITC was driven, at least in part, via reducing the NLRP3 inflammasome activation as indicated by down regulation of NLRP3, TXNIP, capsase-1 and IL-1β, TNF-alpha and IL-6. In conclusion; PEITC attenuated DN progression in a dose dependent manner mainly via interruption of AGE/RAGE and NLPR3/TXNIP/NrF2 crosstalk.

phenethyl isothiocyanatediabetic nephropathyisothiocyanatesglycation
مقالوصول مغلق2021

Phenethyl isothiocyanate alleviates renal injury in STZ‐induced diabetic rats: Effect on oxidative stress, glycative stress and inflammation

The FASEB Journal · مجلد 35 (S1)

Background Diabetic nephropathy (DN) is a serious microvascular complication of diabetes mellitus (DM) and the major cause of end‐stage renal disease. The pathogenesis of DN is multifactorial. Indeed, advanced glycation end products, inflammation and oxidative stress were shown to significantly contribute to DN development/progression. Aim of the work Given the reported beneficial biological effects of phenethyl isothiocyanate (PEITC), the present study aims to evaluate the potential protective effects of PEITC in streptozotocin (STZ)‐induced diabetic Sprague Dawley rats. Methods PEITC was administrated at 3, 10, 30 mg/kg/day for 8 weeks after confirming experimental induction of DM. Renal function (creatinine, urea, proteinuria), hypertrophy index, inflammation (NLRP3/TXNIP/Caspase‐1 and pro‐inflammatory cytokines IL‐1β,TNF‐α, IL‐6), redox homeostasis (Nrf2/Keap1/HO1/γGCS, lipid peroxidation, total antioxidant capacity, and antioxidants GSH, SOD) and protein glycation (AGE/RAGE/GLO1) were assessed by spectrophotometry, ELISA and immunohistochemistry. Moreover, renal structural and ultra‐structural alterations were evaluated. Results According to our results, PEITC administration improved renal function, restored oxidant/antioxidant balance, diminished TXNIP/NLRP3‐dependent inflammation and suppressed glycative stress in a dose dependent manner. Furthermore, results from histological and electron microscopy studies revealed preservation of renal structure by PEITC treatment. Conclusion These findings underline for the first time that PEITC confers a considerable protection against diabetes‐induced kidney injury, suggesting potential use of PEITC as early therapeutic intervene that might slow down the progression of DN via multifactorial pathways targeting.

phenethyl isothiocyanatediabetic nephropathystreptozotocin-induced diabetesoxidative stress